HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.

AuthorsVincenzo Ficarra, Giacomo Novara
JournalEuropean urology (Eur Urol) Vol. 54 Issue 1 Pg. 178 (Jul 2008) ISSN: 0302-2838 [Print] Switzerland
PMID18417274 (Publication Type: Comment, Editorial)
Chemical References
  • Hormone Antagonists
  • Gonadotropin-Releasing Hormone
  • cetrorelix
Topics
  • Dose-Response Relationship, Drug
  • Gonadotropin-Releasing Hormone (administration & dosage, analogs & derivatives, antagonists & inhibitors)
  • Hormone Antagonists (administration & dosage)
  • Humans
  • Male
  • Prostatic Hyperplasia (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: